The Latest Cardiac and Vascular News
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 6 March 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company will remain suspended from quotation at the Company’s request until the beginning of trading on […]
SAN DIEGO, Feb. 19, 2019 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) said today that on 20 February 2019 (AEDT), the Australian Securities Exchange issued a market announcement indicating that the securities of the Company will be suspended from quotation immediately at the Company’s request until the beginning of trading […]
SAN DIEGO, Feb. 04, 2019 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced it is realigning the organization to align with current business conditions. Effective February 8, 2019, REVA will reduce its San Diego-based personnel to 22 employees representing a 44% […]
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” Or The “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of its recently launched Fantom Encore bioresorbable scaffold (BRS) in Italy. The implant procedure was performed by Professor Antonio Colombo at the Columbus Clinic Center in […]
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update and reported financial results for the third quarter ended September 30, 2018. “REVA has achieved two technological milestones in bioresorbable scaffolds (“BRS”): the […]
SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the commercial launch of the Fantom Encore bioresorbable scaffold (“BRS”) and the first implant of Fantom Encore in the FANTOM Post Market Trial. The implant procedure was performed […]
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its third quarter 2018 financial results and provide a business update. The call is scheduled for 2:00 p.m. US PST on Monday, November 5, 2018 (which is 9:00 a.m. AEDT on […]
SAN DIEGO, July 25, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced that its MOTIV™ bioresorbable scaffold is the first drug-eluting bioresorbable scaffold to receive CE Mark approval for treatment of below the knee peripheral artery disease. Late last year, […]
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced it has received CE Mark approval for its full Fantom® Encore product line. This covers Fantom Encore in the 3.0 and 3.5 mm diameters, expanding the approved product line […]
SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom®bioresorbable scaffold (“BRS”) through two years based on data from the FANTOM II trial presented today at the EuroPCR conference in Paris, France. […]
